An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David P Rosenbaum, Ph.D.
Ardelyx, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ardelyx Investigative Site 429
Huntsville, Alabama, United States
- Ardelyx Investigative Site 425
Riverside, California, United States
- Ardelyx Clinical Site 403
Denver, Colorado, United States
- Ardelyx Investigative Site 410
Lauderdale Lakes, Florida, United States
- Ardelyx Investigative Site 430
Miami, Florida, United States
- Ardelyx Investigative Site 427
Meridian, Idaho, United States
- Ardelyx Investigative Site 432
Shreveport, Louisiana, United States
- Ardelyx Investigative Site 415
Bethesda, Maryland, United States
- Ardelyx Investigative Site 402
Kalamazoo, Michigan, United States
- Ardelyx Investigative Site 424
Roseville, Michigan, United States
- Ardelyx Investigative Site 409
Brookhaven, Mississippi, United States
- Ardelyx Investigative Site 417
Columbus, Mississippi, United States
- Ardelyx Investigative Site 431
Tupelo, Mississippi, United States
- Ardelyx Investigative Site 423
St Louis, Missouri, United States
- Ardelyx Investigative Site 416
Albuquerque, New Mexico, United States
- Ardelyx Investigative Site 419
The Bronx, New York, United States
- Ardelyx Investigative Site 408
Asheville, North Carolina, United States
- Ardelyx Investigative Site 411
Charlotte, North Carolina, United States
- Ardelyx Investigative Site 420
New Bern, North Carolina, United States
- Ardelyx Investigative Site 426
Raleigh, North Carolina, United States
- Ardelyx Investigative Site 412
Wilmington, North Carolina, United States
- Ardelyx Investigative Site 414
Bethlehem, Pennsylvania, United States
- Ardelyx Investigative Site 404
Columbia, South Carolina, United States
- Ardelyx Investigative Site 421
Orangeburg, South Carolina, United States
- Ardelyx Investigative Site 428
Sumter, South Carolina, United States
- Ardelyx Investigative Site 413
Knoxville, Tennessee, United States
- Ardelyx Investigative Site 418
Nashville, Tennessee, United States
- Ardelyx Investigative Site 406
Austin, Texas, United States
- Ardelyx Investigative Site 405
Bellville, Texas, United States
- Ardelyx Investigative Site 407
San Antonio, Texas, United States
- Ardelyx Investigative Site 422
San Antonio, Texas, United States
- Ardelyx Investigative Site 401
St. George, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2016
- Primary completion
- 31 Dec 2016
- Completion
- 17 Jan 2018
- Last update posted
- 10 Aug 2020
- Registered enrollment
- 219
- Registry id
- NCT02675998
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.